The company reveals its anti-GPRC5D T-cell engager.

The company admits defeat with zelenectide.

But this comes in second-line breast cancer, a use the group isn’t pursuing.

Ascentage hopes to become a new force in BTK.

Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.

Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.